KentWilliamMouwMD

Radiation Oncologist, Brigham & Women's Hospital/Dana-Farber Cancer Institute

Dr. Mouw is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2011 - 2015
Brigham and Women's HospitalInternship, Internal Medicine, 2010 - 2011
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2010

PubMed

Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.
Dag Rune Stormoen, Signe Lehn, Kent W Mouw, Zoltan Szallasi, Linea Cecilie Melchior
Scientific Reports. 2024-11-10
2 citations
Insulin resistance during androgen deprivation therapy in men with prostate cancer.
Shehzad Basaria, Mary-Ellen Taplin, Marie McDonnell, Donald C Simonson, Alexander P Lin
Cancer. 2024-11-01
Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer.
Vincent D D'Andrea, Christopher J Magnani, John Ernandez, Joaquim Bellmunt, Matthew Mossanen
Current Urology Reports. 2024-10-09

Journal Articles

Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic
Kent W Mouw, Paul L Nguyen, JAMA Oncology

Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 PandemicAugust 2020
Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 PandemicAugust 2020

Active Surveillance for Low-Risk Prostate Cancer in Black PatientsMay 22nd, 2019